title: Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (chapter 9).
abstract: In the UK, there is a continuing year-on-year trend towards improvement in serum phosphate control in dialysis patients although overall it still remains poor. The Renal Association (RA) target (<1.8 mmol/l) was achieved in 65% of patients overall, (71% of peritoneal dialysis (PD) patients, 63% of haemo dialysis (HD) patients). Seventy-six percent of UK dialysis patients achieve a corrected calcium concentration within the RA target range. As with serum phosphate, there is a trend of continuing year-on-year improvement. Nearly two-thirds (69%) of patients achieve a calcium x phosphate product within the KDOQI guidelines (<4.4 mmol(2)/l(2)): again, achievement seems to have improved year-on-year. Control was better in PD patients compared with HD patients (73% vs 67% achieving the standard). There remains large between-centre variation in the ability of renal centres to achieve the UK RA target for plasma parathyroid hormone (PTH). As seen in previous years, overall achievement was poor (median 63%, range 47-92% compliance with the standard). Most transplant patients achieve good phosphate and calcium control (99%, range 95-100%) and the percentage of patients achieving serum calcium concentrations within the target range was 84% (range 43-97%). Nearly all (99%) of transplant patients achieved calcium x phosphate product concentrations within the KDOQI target range. There would appear to be wide variation in clinical practice with respect to aluminium monitoring with a suggestion that few centres are following current UK, RA guidelines. Overall in the UK, 83% of HD, 70% of PD and 62% of transplant patients achieve a total cholesterol concentration <5 mmol/l. The percentage of patients with cholesterol <5 mmol/l has increased significantly year-on-year in all three modalities.
authors.affiliation: Department of Clinical Biochemistry, East Kent Hospitals NHS Trust, Kent and Canterbury Hospital, Canterbury, Kent CT1 3NG, UK. Edmund.lamb@ekht.nhs.uk
authors.forename: Edmund J
authors.initials: EJ
authors.lastname: Lamb
authors.forename: Alex
authors.initials: A
authors.lastname: Hodsman
authors.forename: Dirk
authors.initials: D
authors.lastname: van Schalkwyk
authors.forename: David
authors.initials: D
authors.lastname: Ansell
authors.forename: Graham
authors.initials: G
authors.lastname: Warwick
mesh_terms: D000418:Albumins / Q000378:metabolism; D000535:Aluminum / Q000097:blood; D002118:Calcium / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D015331:Cohort Studies; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood* / Q000628:therapy*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood*; D012042:Registries / Q000706:statistics & numerical data; D017582:Renal Replacement Therapy / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D006113:United Kingdom
chemical_list: D000418:Albumins; D010281:Parathyroid Hormone; D010710:Phosphates; D002784:Cholesterol; D000535:Aluminum; D002118:Calcium